Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00432003 · ClinicalTrials.gov registry record

Effects of Anti-HIV Therapy on Nervous System Function

A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
297
Enrollment target

NCT00432003: Completed study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT00432003 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 297 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00432003 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
297 participants
Enrollment target

Study Summary

The purpose of this study is to observe the way two different anti-HIV treatment strategies affect nerve and brain function in adults with HIV.

Trial Details

FieldValue
Enrollment Target 297 participants
Start Date 2005-03
Est. Completion 2007-07

What the finished NCT00432003 record still lists

NCT00432003 is an observational study that tracks outcomes without assigning an intervention. The registered 297 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT00432003 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00432003 about?

NCT00432003 is a clinical study titled "Effects of Anti-HIV Therapy on Nervous System Function". The purpose of this study is to observe the way two different anti-HIV treatment strategies affect nerve and brain function in adults with HIV.

What is the current status of trial NCT00432003?

This trial is currently completed. The enrollment target is 297 participants. The study started on 2005-03. Estimated completion is 2007-07.

Who is sponsoring clinical trial NCT00432003?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06309160 · 297 participants · NA

    COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD

  • NCT06375811 · 297 participants · Phase 3

    Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp

  • NCT07222215 · 297 participants · Phase 2

    PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

  • NCT06305624 · 298 participants · NA

    Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00432003, the US trial registry maintained by the National Library of Medicine. NCT00432003 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.